Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background Despite remarkable results with salvage standard-dose or high-dose chemotherapy ∼15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT.Patients and methods Single arm phase II trial investigating pembrolizumab 200 mg i.v. Q3weeks until disease progression in patients with relapsed GCT and no curable options. Patients age ≥18 with GCT who progressed after first-line cisplatin-based chemotherapy and after at least one salvage regimen (high-dose or standard-dose chemotherapy) were eligible. Centrally assessed programmed death-ligand 1 (PD-L1) on tumor and infiltrating immune cells was scored. Primary end point was overall response rate using immune-related response criteria. Simon two-stage design with type I error 20% and power 80% was utilized.Results Twelve male patients were enrolled. Median age was 38 years. All patients had nonseminoma. Primary site was testis (11) or mediastinum (1). Median AFP 615 (range 1-32, 760) and hCG 4 (range 0.6-37, 096). Six patients had late relapse (>2 years). Median number of previous chemotherapy regimens was 3. Six patients received prior high-dose chemotherapy. Two patients had positive PD-L1 staining (H-score 90 and 170). Median number of pembrolizumab doses was 2 (range 1-8). There were six grade 3 adverse events. No immune-related adverse events were reported. No partial or complete responses were observed. Two patients achieved radiographic stable disease for 28 and 19 weeks, respectively; both had continued rising AFP level despite radiographic stability and had negative PD-L1 staining.Conclusion This is the first reported trial evaluating immune checkpoint inhibitors in GCT. Pembrolizumab is well tolerated but does not appear to have clinically meaningful single-agent activity in refractory GCT.Clinical trial information NCT02499952.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“their corresponding tumors lacked PD-L1 expression on immunochemical staining [50].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“In the course of this study, there were no partial or complete response noted.”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“both of these patients exhibited ongoing increases in AFP levels despite radiographic stability”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“Among the total of 12 patients, only two of them experienced radiographically stable disease, which persisted for 28 and 19 weeks, respectively.”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 1×
“Higher levels of PD-L1 expression have been associated with robust responses in certain advanced solid tumors such as melanoma and lung cancer but not in others [10, 11].”
BackgroundOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 1×
“A Simon two-stage optimal design with type I error rate of 20% and power of 80% was utilized [17].”
MethodPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · cited 1×
“This might have been a short interval given our understanding that the immune checkpoint inhibitors have a median time to response of 2 months [8, 10].”
BackgroundSelf-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · cited 1×
“The expression of PD-L1 is known to be dynamic and is regulated by extrinsic signaling such as release of interferon-c by immune cells, loss of expression of tumor suppressor genes or activation of the AKT-mTOR pathway [27, 28].”
BackgroundHigh-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496
Self-citationKondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.638 · Cited by 418
Cited by
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Cheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Self-citationRuan, H., Hu, Q., Wen, D., Chen, Q., Chen, G., Lu, Y., Wang, J., Cheng, H., Lu, W., & Gu, Z. (2019) · Advanced Materials · doi:10.1002/adma.201806957 · Cited by 220
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Zhao, B., Zhao, H., & Zhao, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937612 · Cited by 207
Testicular germ cell tumor: a comprehensive review
Batool, A., Karimi, N., Wu, X.-N., Chen, S.-R., & Liu, Y.-X. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03022-7 · Cited by 168
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Jia, Q., Wang, J., He, N., He, J., & Zhu, B. (2019) · JCI Insight · doi:10.1172/jci.insight.127901 · Cited by 158
Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities
de Vries, G., Rosas-Plaza, X., van Vugt, M. A. T. M., Gietema, J. A., & de Jong, S. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102054 · Cited by 161
Immune Checkpoint Inhibitor–Induced Cardiotoxicity: A Systematic Review and Meta-Analysis
Nielsen, D. L., Juhl, C. B., Nielsen, O. H., Chen, I. M., & Herrmann, J. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.3065 · Cited by 154
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Fan, Q., Chen, Z., Wang, C., & Liu, Z. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802540 · Cited by 129
McGregor, B. A., Campbell, M. T., Xie, W., Farah, S., Bilen, M. A., Schmidt, A. L., Sonpavde, G., Kilbridge, K. L., Choudhury, A. D., Mortazavi, A., et al. (2020) · Cancer · doi:10.1002/cncr.33328 · Cited by 123
Advances in diagnosis and treatment of testicular cancer
Chovanec, M., & Cheng, L. (2022) · BMJ · doi:10.1136/bmj-2022-070499 · Cited by 102
Systemic immune-inflammation index in germ-cell tumours
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Kalavska, K., Rejlekova, K., Svetlovska, D., Macak, D., Spanik, S., Kajo, K., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.460 · Cited by 90
“A phase II clinical study from Indiana University evaluating an anti-PD-1 agent pembrolizumab failed to prove an efficacy in the treatment of refractory GCTs (Adra et al, 2017).”
BackgroundNon-Epithelial Ovarian Cancers: How Much Do We Really Know?
Cheung, A., Shah, S., Parker, J. S., Soor, P., Limbu, A., Sheriff, M., & Boussios, S. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031106 · Cited by 89
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 96
Primary mediastinal germ cell tumors
Rosti, G., Secondino, S., Necchi, A., Fornarini, G., & Pedrazzoli, P. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.04.001 · Cited by 88
Phase II Study of Avelumab in Multiple Relapsed/Refractory Germ Cell Cancer
Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., & Mardiak, J. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00805-4 · Cited by 81
Necchi, A., Giannatempo, P., Raggi, D., Mariani, L., Colecchia, M., Farè, E., Monopoli, F., Calareso, G., Ali, S. M., Ross, J. S., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.09.010 · Cited by 78
Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours
Saani, I., Raj, N., Sood, R., Ansari, S., Mandviwala, H. A., Sanchez, E., & Boussios, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20126089 · Cited by 78
Lobo, J., Rodrigues, Â., Guimarães, R., Cantante, M., Lopes, P., Maurício, J., Oliveira, J., Jerónimo, C., & Henrique, R. (2019) · Cancers · doi:10.3390/cancers11101535 · Cited by 69
Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives
Lobo, J., Jerónimo, C., & Henrique, R. (2020) · Cancers · doi:10.3390/cancers12061601 · Cited by 64
Immunotherapy in Testicular Germ Cell Tumors
Kaľavská, K., Schmidtova, S., Chovanec, M., & Mego, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.573977 · Cited by 61
Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy
Necchi, A., Bratslavsky, G., Corona, R. J., Chung, J. H., Millis, S. Z., Elvin, J. A., Vergilio, J.-A., Suh, J., Ramkissoon, S., Severson, E., et al. (2020) · European Urology Focus · doi:10.1016/j.euf.2018.07.013 · Cited by 52
Yu, P., Zhu, C., You, X., Gu, W., Wang, X., Wang, Y., Bu, R., & Wang, K. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06837-w · Cited by 50
Overcoming Chemotherapy Resistance in Germ Cell Tumors
Országhová, Z., Kaľavská, K., Mego, M., & Chovanec, M. (2022) · Biomedicines · doi:10.3390/biomedicines10050972 · Cited by 51
Maoz, A., Matsuo, K., Ciccone, M. A., Matsuzaki, S., Klar, M., Roman, L. D., Sood, A. K., & Gershenson, D. M. (2020) · Cancers · doi:10.3390/cancers12061398 · Cited by 48
Contemporary management of ovarian germ cell tumors and remaining controversies
Veneris, J. T., Mahajan, P., & Frazier, A. L. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.05.007 · Cited by 45
Therapeutic approaches for refractory germ cell cancer
Oing, C., Seidel, C. A., & Bokemeyer, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1450630 · Cited by 45
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors
Tsimberidou, A.-M., Vo, H. H., Subbiah, V., Janku, F., Piha-Paul, S., Yilmaz, B., Gong, J., Naqvi, M. F., Tu, S.-M., Campbell, M., et al. (2021) · The Oncologist · doi:10.1002/onco.13682 · Cited by 43
Lobo, J., Guimarães‐Teixeira, C., Barros‐Silva, D., Miranda‐Gonçalves, V., Camilo, V., Guimarães, R., Cantante, M., Braga, I. C., Maurício, J., Oing, C., et al. (2020) · Cancers · doi:10.3390/cancers12102903 · Cited by 42
Epigenetics and Testicular Cancer: Bridging the Gap Between Fundamental Biology and Patient Care
Nicu, A.-T., Medar, C., Chifiriuc, M. C., Pîrcălăbioru, G. G., & Burlibaşa, L. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.861995 · Cited by 45
Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
Ruan, H., Bu, L., Hu, Q., Cheng, H., Lu, W., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201801099 · Cited by 42
Oing, C., Skowron, M. A., Bokemeyer, C., & Nettersheim, D. (2019) · Andrology · doi:10.1111/andr.12611 · Cited by 40
Chen, G., Wang, W., Wei, X., Chen, Y., Peng, L., Qu, R., Luo, Y., He, S., Liu, Y., Du, J., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6343 · Cited by 39
Necchi, A., Bratslavsky, G., Chung, J., Millis, S. Z., Gay, L. M., Ali, S. M., & Ross, J. S. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0430 · Cited by 35
Testicular Cancer: Biology to Bedside
King, J. M., Adra, N., & Einhorn, L. H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1452 · Cited by 34
Self-citationZhang, Y., Chen, J., Liu, H., Dai, J., Zhao, J., Zhu, S., Zhang, X., Liang, J., Hu, X., Zhao, J., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102787 · Cited by 34
Schmidtova, S., Kaľavská, K., Lišková, V., Plavá, J., Miklikova, S., Kučerová, L., Matúšková, M., Rojikova, L., Čierna, Z., Rogozea, A. L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084263 · Cited by 32
Self-citationLabadie, B. W., Balar, A. V., & Luke, J. J. (2021) · Cancers · doi:10.3390/cancers13215415 · Cited by 37
Immune mechanisms and possible immune therapy in testicular germ cell tumours
Chovanec, M., Mardiak, J., & Mego, M. (2019) · Andrology · doi:10.1111/andr.12656 · Cited by 32
Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice
Chovanec, M., Albany, C., Mego, M., Montironi, R., Cimadamore, A., & Cheng, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00571 · Cited by 32
Self-citationEpigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment “jigsaw puzzle”
Dzobo, K. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0206 · Cited by 29
Schepisi, G., Gianni, C., Cursano, M. C., Gallá, V., Menna, C., Casadei, C., Bleve, S., Lolli, C., Martinelli, G., Rosti, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118610 · Cited by 29
Immunotherapy: Last Bullet in Platinum Refractory Germ Cell Testicular Cancer
Semaan, A., Haddad, F., Eid, R., Kourié, H. R., & Nemr, E. (2019) · Future Oncology · doi:10.2217/fon-2018-0571 · Cited by 29
Lobo, J., Constâncio, V., Leite-Silva, P., Guimarães, R., Cantante, M., Braga, I., Maurício, J., Looijenga, L. H. J., Henrique, R., & Jerónimo, C. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01048-y · Cited by 28
Palliative treatment of germ cell cancer
Oing, C., Giannatempo, P., Honecker, F. U., Oechsle, K., Bokemeyer, C., & Beyer, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.007 · Cited by 28
Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies
Pignot, G., Loriot, Y., Kamat, A. M., Shariat, S. F., & Plimack, E. R. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.01.002 · Cited by 28
Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors
Giorgi, U. D., Casadei, C., Bergamini, A., Attademo, L., Cormio, G., Lorusso, D., Pignata, S., & Mangili, G. (2019) · Cancers · doi:10.3390/cancers11101584 · Cited by 29
Sadigh, S., Farahani, S. J., Shah, A., Vaughn, D., & Lal, P. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz184 · Cited by 26
Self-citationImmunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
Jang, A., Adler, D. M., Rauterkus, G. P., Bilen, M. A., & Barata, P. C. (2021) · Cancers · doi:10.3390/cancers13205065 · Cited by 27
Current pharmacotherapy for testicular germ cell cancer
Alsdorf, W. H., Seidel, C. A., Bokemeyer, C., & Oing, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1583745 · Cited by 28
Targeted treatment approaches in refractory germ cell tumors
Gálvez, L., Sánchez‐Muñoz, A., Ribelles, N., Sáez, M. I., Baena, J., Ruíz, S., Ithurbisquy, C., & Alba, E. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.005 · Cited by 26
Takamori, S., Takada, K., Toyokawa, G., Azuma, K., Shimokawa, M., Jogo, T., Yamada, Y., Hirai, F., Tagawa, T., Kawahara, A., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12933 · Cited by 23
Targeting the Immune system and Epigenetic Landscape of Urological Tumors
Lobo, J., Jerónimo, C., & Henrique, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030829 · Cited by 23
Immune Checkpoint Inhibitors in Genitourinary Malignancies
Thana, M., & Wood, L. A. (2020) · Current Oncology · doi:10.3747/co.27.5121 · Cited by 23
Skowron, M. A., Kotthoff, M., Bremmer, F., Ruhnke, K., Parmaksiz, F., Richter, A., Küffer, S., Reuter‐Jessen, K., Pauls, S., Stefanski, A., et al. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00636-3 · Cited by 24
Cancer Stem Cell Niche and Immune-Active Tumor Microenvironment in Testicular Germ Cell Tumors
Kaľavská, K., Kučerová, L., Schmidtova, S., Chovanec, M., & Mego, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36214-0_9 · Cited by 23
Kawahara, T., Kawai, K., Kojima, T., Nagumo, Y., Sakka, S., Kandori, S., Negoro, H., Mathis, B. J., Maruo, K., Miura, K., et al. (2022) · International Journal of Urology · doi:10.1111/iju.14885 · Cited by 25
Ouyang, T., Cao, Y., Kan, X., Chen, L., Ren, Y., Sun, T., Yan, L., Xiong, B., Liang, B., & Zheng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621639 · Cited by 23
Primary germ cell tumours of the mediastinum: A review with emphasis on diagnostic challenges
Fichtner, A., Marx, A., Ströbel, P., & Bremmer, F. (2023) · Histopathology · doi:10.1111/his.15090 · Cited by 20
Mediastinal germ cell tumours: where we are and where we are going—a narrative review
Marandino, L., & Vogl, U. M. (2021) · Mediastinum · doi:10.21037/med-21-33 · Cited by 22
Genetics of testicular germ cell tumors
Singla, N., Lafin, J. T., Ghandour, R. A., Kaffenberger, S. D., Amatruda, J. F., & Bagrodia, A. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000642 · Cited by 19
Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center
Ji, Y. S., & Park, S. H. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.1066 · Cited by 18
Malignant germ cells tumor of the ovary
Maria, F. D., Amant, F. C., Chiappa, V., Paolini, B., Bergamini, A., Fruscio, R., Corso, G., Raspagliesi, F., & Bogani, G. (2025) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2025.36.e108 · Cited by 19
Contemporary management of early stage testicular seminoma
Aydın, A. M., Zemp, L. W., Cheriyan, S., Sexton, W. J., & Johnstone, P. A. S. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2019.09.32 · Cited by 17
Steineck, A., Krumm, N., Sarthy, J. F., Pritchard, C. C., Chapman, T., Stacey, A. W., Vitanza, N. A., & Cole, B. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00028 · Cited by 17
Phase II Trial of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Ashkar, R., Feldman, D. R., Adra, N., Zaid, M. A., Funt, S. A., Althouse, S. K., Perkins, S. M., Snow, C. I., Lazzara, K. M., Sego, L. M., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01134-1 · Cited by 16
“Initial trials investigating single agent immune checkpoint inhibition with pembrolizumab in patients with refractory GCT have been disappointing as well with no objective responses reported [27].”
BackgroundSelf-citationPęksa, R., Kunc, M., Popęda, M., Piątek, M., Bieńkowski, M., Żok, J., Starzyńska, A., Perdyan, A., Sowa, M., Duchnowska, R., et al. (2021) · Cancers · doi:10.3390/cancers13081750 · Cited by 16
“Unfortunately, recent findings suggest that immune-checkpoint inhibitors (durvalumab plus tremelimumab or pembrolizumab) are mainly ineffective in patients with advanced GCTs [54,55].”
BackgroundMolecular Characterization of Testicular Germ Cell Tumors: Chasing the Underlying Pathways
Chovanec, M., & Liang Cheng, C. (2018) · Future Oncology · doi:10.2217/fon-2018-0617 · Cited by 16
Recent advances in testicular germ cell tumours
Mele, T., Reid, A., & Huddart, R. A. (2021) · Faculty Reviews · doi:10.12703/r/10-67 · Cited by 17
Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers
Contos, G., Baca, Y., Xiu, J., Brown, J., Holloway, R., Korn, W. M., Herzog, T. J., Jones, N., & Winer, I. S. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.09.011 · Cited by 16
Güven, D. C., Stephen, B., Şahin, T. K., Çakır, İ. Y., Erul, E., & Aksoy, S. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103700 · Cited by 15
Urbini, M., Schepisi, G., Bleve, S., Virga, A., Gianni, C., Gurioli, G., Ulivi, P., & Giorgi, U. D. (2021) · Cancers · doi:10.3390/cancers13205223 · Cited by 16
PD-L1 and PD-1 expression in pediatric central nervous system germ cell tumors
Woods, J. K., Lidov, H. G. W., Ligon, K. L., Santagata, S., Chi, S. N., Yeo, K. K., & Alexandrescu, S. (2022) · Modern Pathology · doi:10.1038/s41379-022-01142-3 · Cited by 14
Immunotherapy in rare ovarian cancer
Laga, T., Vergote, I. B., & Nieuwenhuysen, E. V. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000759 · Cited by 13
Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)
Hodroj, K., Stevovic, A., Attignon, V., Ferraioli, D., Méeus, P., Croce, S., Chopin, N., Rossi, L., Floquet, A., Rousset‐Jablonski, C., et al. (2021) · Cancers · doi:10.3390/cancers13020220 · Cited by 15
Taza, F., Abonour, R., Zaid, M. I. A., Althouse, S. K., Anouti, B., Akel, R., Hanna, N. H., Adra, N., & Einhorn, L. H. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.01.004 · Cited by 13
Self-citationExpression of the immune checkpoint receptor TIGIT in seminoma
Hinsch, A., Blessin, N., Simon, R., Kluth, M., Fischer, K., Hube‑Magg, C., Li, W., Makrypidi‑Fraune, G., Wellge, B., Mandelkow, T., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10428 · Cited by 12
Secondino, S., Badoglio, M., Rosti, G., Labopin, M., Delaye, M., Bokemeyer, C., Seidel, C. A., Kanfer, E., Metafuni, E., Finke, J., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103692 · Cited by 13
Pasquale, M. D. D., D’Angelo, P., Crocoli, A., Boldrini, R., Conte, M., Bisogno, G., Spreafico, F., Inserra, A., Biasoni, D., Dall’Igna, P., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28125 · Cited by 12
Epigenetic Factors and ncRNAs in Testicular Cancer
Nuñez-Corona, D., Contreras-Sanzón, E., Puente-Rivera, J., Arreola, R., Camacho-Nuez, M., Santiago, J. C., Estrella-Parra, E. A., Torres‐Romero, J. C., López‐Camarillo, C., & Álvarez-Sánchez, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512194 · Cited by 12
Lei, N., Lei, L.-L., Wang, C.-H., & Mei, C. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2699 · Cited by 12
Managing seminomatous and nonseminomatous germ cell tumors
Chahoud, J., Zhang, M., Shah, A. Y., Lin, S.-H., Pisters, L. L., & Tu, S. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000446 · Cited by 12
Cimadamore, A., Scarpelli, M., Santoni, M., Massari, F., Tartari, F., Cerqueti, R., Antonio Lopez-beltran, B., Liang Cheng, C., & Montironi, R. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190225124352 · Cited by 13
Wood, M. J., Thomas, R., Howard, S. A. H., & Braschi‐Amirfarzan, M. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.19.21623 · Cited by 12
Primary mediastinal germ cell tumours: real world experience in the low middle income (LMIC) setting
Joel, A., Mathew, N., Andugala, S. S., Daniel, S., Gnanamuthu, B. R., John, A. O., Georgy, J. T., Chacko, R. T., Irodi, A., Yadav, B., et al. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1186 · Cited by 12
Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J. (2024) · Cancers · doi:10.3390/cancers16020428 · Cited by 11
“However, it is worth noting that both of these patients exhibited ongoing increases in AFP levels despite radiographic stability, and their corresponding tumors lacked PD-L1 expression on immunochemical staining [50].”
BackgroundKawai, K., Tawada, A., Onozawa, M., Inoue, T., Sakurai, H., Mori, I., Takiguchi, Y., & Miyazaki, J. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s323898 · Cited by 11
Pierantoni, F., Maruzzo, M., Bimbatti, D., Finotto, S., Marino, D., Galiano, A., Basso, U., & Zagonel, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103568 · Cited by 11
Sardana, R., Mishra, S. K., Williamson, S. R., Mohanty, A., & Mohanty, S. K. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.09.002 · Cited by 11
Ussowicz, M., Mielcarek‐Siedziuk, M., Musiał, J., Stachowiak, M., Węcławek‐Tompol, J., Sęga-Pondel, D., Frączkiewicz, J., Trelińska, J., & Raciborska, A. (2020) · Cancers · doi:10.3390/cancers12123841 · Cited by 11
Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non-ovarian Solid Malignancies
Hack, J., & Crabb, S. J. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.02.015 · Cited by 13
Holdase/Foldase Mimetic Nanochaperone Improves Antibody‐Based Cancer Immunotherapy
Zhang, Y., Fu, H., Chen, J., Xu, L., An, Y., Ma, R., Zhu, C., Liu, Y., Ma, F., & Shi, L. (2022) · Small Methods · doi:10.1002/smtd.202201051 · Cited by 11
Light, A., Ahmed, A., Dasgupta, P., & Elhage, O. (2020) · British Journal of Urology · doi:10.1111/bju.15084 · Cited by 10
Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review
Petrelli, F., Consoli, F., Ghidini, A., Perego, G., Luciani, A., Mercurio, P., Berruti, A., & Grisanti, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720748 · Cited by 11
Management of Refractory Germ Cell Cancer
Lorch, A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201189 · Cited by 10
Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy
McGregor, B. A., & Sonpavde, G. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.03.011 · Cited by 10
Management of malignant dysgerminoma of the ovary
Arndt, T., TAUBE, E. T., Deubzer, H. E., Rothe, K., Calaminus, G., Sehouli, J., & Pietzner, K. (2022) · European Journal of Gynaecological Oncology · doi:10.31083/j.ejgo4302041 · Cited by 10
Huang, W., Zheng, Z., Bao, Z., Xiao, X., Li, L., Sun, Z., & Kang, L. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1382672 · Cited by 9
Immuno-Oncology Advances in Genitourinary Cancers
Zang, P. D., Angeles, A., Dorff, T. B., Pal, S. K., & Gupta, S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_430428 · Cited by 9
Metadata
- Authors
- Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H.
- Affiliations
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center (US)
- Indiana University School of Medicine (US)
- Hoosier Cancer Research Network (United States) (US)
- Abramson Cancer Center (US)
- Corresponding author
- Adra, N.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 29
- Issue
- 1
- Pages
- 209-214
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2765537501
- Cited by
- 196
- References
- 28
- Citations by year
- 2026: 18 · 2025: 11 · 2024: 28 · 2023: 19 · 2022: 18 · 2021: 29 · 2020: 24 · 2019: 28 · 2018: 18
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 722 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- pembrolizumab, germ cell tumors, non-seminoma, platinum-refractory disease, immune checkpoint inhibitors, PD-L1 expression, immunotherapy, overall response rate, alpha-fetoprotein, immune-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Humans, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Biomarkers, Tumor, Salvage Therapy, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.